A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFERRAROTTO, Renata
dc.contributor.authorMACHADO, Karime
dc.contributor.authorMAK, Milena P.
dc.contributor.authorSHAH, Neeraj
dc.contributor.authorTAKAHASHI, Tiago K.
dc.contributor.authorCOSTA, Frederico P.
dc.contributor.authorOVERMAN, Michael J.
dc.contributor.authorKOPETZ, Scott
dc.contributor.authorHOFF, Paulo M.
dc.date.accessioned2013-07-30T17:51:49Z
dc.date.available2013-07-30T17:51:49Z
dc.date.issued2012
dc.description.abstractBackground: A considerable number of metastatic colorectal cancer (mCRC) patients who progress on standard treatment with 5-fluorouracil (5FU), oxaliplatin, irinotecan and monoclonal antibodies, still have adequate performance status and desire further treatment. Mitomycin C (MMC) has been widely used in this context, and despite good tolerability, there are doubts regarding its true benefit. Methods: In order to assess the activity of MMC in the refractory mCRC setting, we retrospectively evaluated 109 heavily pre-treated patients who received MMC as single agent or in combination for mCRC at three different institutions in two countries. Results: Median patient's age was 54 years old, 57% were male and 94% had performance status ECOG 0 or 1. MMC was used in second line in 11%, third line in 38% and fourth line or beyond in 51% of patients. 58% received MMC combinations, mainly with capecitabine. Grade 3 or 4 toxicity was observed in 5% of patients and 6% required dose reductions. Median time to treatment failure (TTF) was 1.7 months with MMC and 3.6 months on the regimen prior to MMC, with a ratio between these TTF below 1 in 82% of patients. Median survival was only 4.5 months (95% confidence interval (CI) of 3.48-5.56). Conclusions: This retrospective data represent the largest reported series of unselected refractory mCRC patients treated with MMC. The median survival of 4.5 months is similar to the survival expected for best supportive care. This lack of activity strongly suggests that MMC should not be routinely used in refractory mCRC.
dc.description.indexMEDLINE
dc.identifier.citationEUROPEAN JOURNAL OF CANCER, v.48, n.6, p.820-826, 2012
dc.identifier.doi10.1016/j.ejca.2012.01.008
dc.identifier.issn0959-8049
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1423
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.relation.ispartofEuropean Journal of Cancer
dc.rightsrestrictedAccess
dc.rights.holderCopyright ELSEVIER SCI LTD
dc.subjectMitomycin C
dc.subjectMetastatic colorectal cancer
dc.subjectRefractory setting
dc.subject.otherrandomized phase-iii
dc.subject.other1st-line treatment
dc.subject.other3rd-line chemotherapy
dc.subject.othercontinuous-infusion
dc.subject.other2nd-line treatment
dc.subject.otheririnotecan
dc.subject.otherfluorouracil
dc.subject.othercapecitabine
dc.subject.other5-fluorouracil
dc.subject.otheroxaliplatin
dc.subject.wosOncology
dc.titleA multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalFERRAROTTO, Renata:Hosp Sirio Libanes, Dept Clin Oncol, BR-01308050 Sao Paulo, Brazil
hcfmusp.author.externalSHAH, Neeraj:Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol Dept, Houston, TX 77030 USA
hcfmusp.author.externalCOSTA, Frederico P.:Hosp Sirio Libanes, Dept Clin Oncol, BR-01308050 Sao Paulo, Brazil
hcfmusp.author.externalOVERMAN, Michael J.:Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol Dept, Houston, TX 77030 USA
hcfmusp.author.externalKOPETZ, Scott:Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol Dept, Houston, TX 77030 USA
hcfmusp.citation.scopus13
hcfmusp.contributor.author-fmusphcKARIME KALIL MACHADO
hcfmusp.contributor.author-fmusphcMILENA PEREZ MAK
hcfmusp.contributor.author-fmusphcTIAGO KENJI TAKAHASHI
hcfmusp.contributor.author-fmusphcPAULO MARCELO GEHM HOFF
hcfmusp.description.beginpage820
hcfmusp.description.endpage826
hcfmusp.description.issue6
hcfmusp.description.volume48
hcfmusp.lim.ref2012
hcfmusp.origemWOS
hcfmusp.origem.pubmed22330318
hcfmusp.origem.scopus2-s2.0-84862815695
hcfmusp.origem.wosWOS:000302122000005
hcfmusp.publisher.cityOXFORD
hcfmusp.publisher.countryENGLAND
hcfmusp.relation.referenceArkenau HT, 2009, ONCOLOGY-BASEL, V76, P151, DOI 10.1159/000195884
hcfmusp.relation.referenceChester JD, 2000, ANN ONCOL, V11, P235, DOI 10.1023/A:1008356017611
hcfmusp.relation.referenceChong G, 2005, BRIT J CANCER, V93, P510, DOI 10.1038/sj.bjc.6602733
hcfmusp.relation.referenceFuchs CS, 2007, J CLIN ONCOL, V25, P4779, DOI 10.1200/JCO.2007.11.3357
hcfmusp.relation.referenceGyldenkerne N, 2004, ACTA ONCOL, V43, P276, DOI 10.1080/02841860410028655
hcfmusp.relation.referenceHurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
hcfmusp.relation.referenceJonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
hcfmusp.relation.referenceLim DH, 2005, CANCER CHEMOTH PHARM, V56, P10, DOI 10.1007/s00280-004-0963-2
hcfmusp.relation.referenceWolmark N, 1998, J CLIN ONCOL, V16, P301
hcfmusp.relation.referenceMOERTEL CG, 1968, J AMER MED ASSOC, V204, P1045, DOI 10.1001/jama.204.12.1045
hcfmusp.relation.referenceParkin DM, 2005, CA-CANCER J CLIN, V55, P74
hcfmusp.relation.referencePeeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055
hcfmusp.relation.referencePrice Timothy J, 2004, Clin Colorectal Cancer, V3, P235, DOI 10.3816/CCC.2004.n.004
hcfmusp.relation.referenceRao S, 2004, BRIT J CANCER, V91, P839, DOI 10.1038/sj.bjc.6602039
hcfmusp.relation.referenceRimassa L, 2006, TUMORI, V92, P285
hcfmusp.relation.referenceRosati G, 2003, ANTICANCER RES, V23, P2981
hcfmusp.relation.referenceRoss P, 1997, ANN ONCOL, V8, P995, DOI 10.1023/A:1008263516099
hcfmusp.relation.referenceRougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2
hcfmusp.relation.referenceRougier P, 2002, ANN ONCOL, V13, P1558, DOI 10.1093/annonc/mdf259
hcfmusp.relation.referenceScheithauer W, 2002, CANCER INVEST, V20, P60, DOI 10.1081/CNV-120000367
hcfmusp.relation.referenceTebbutt NC, 2010, J CLIN ONCOL, V28, P3191, DOI 10.1200/JCO.2009.27.7723
hcfmusp.relation.referenceTournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
hcfmusp.relation.referenceVaklavas C, 2011, CANCER-AM CANCER SOC, V117, P77, DOI 10.1002/cncr.25346
hcfmusp.relation.referenceVan Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
hcfmusp.relation.referenceYamada Y, 2003, CANCER CHEMOTH PHARM, V52, P125, DOI 10.1007/s00280-003-0604-1
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublication50fdeb3e-ad12-4671-823d-b1205892a112
relation.isAuthorOfPublication9855245b-2b6e-4198-a55e-a5caf9026f9f
relation.isAuthorOfPublication5e368f73-c680-413f-9d30-a1d60e9fd6b9
relation.isAuthorOfPublication706efa42-09fc-4065-8330-9391f2cbe840
relation.isAuthorOfPublication.latestForDiscovery706efa42-09fc-4065-8330-9391f2cbe840
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_MACHADO_A_multicenter_multinational_analysis_of_mitomycin_C_in_2012.PDF
Tamanho:
366.08 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24